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peanut 5 (21%), egg 3 (13%), fish 1 (4%) and fruits 1 (4%). Peanut could be reintroduced 
to all children after CRD, egg and milk after specific IgE IVD. Prior to the introduction 
of food a secondary care specialist food provocation was performed to confirm the 
IVD result. ConClusions: CRD ISAC was beneficial in 54% of the cases and in 21% 
of the cases it was critical for decision making. The aim of the study was reached as 
avoidance diets decreased by 63%. The results indicate, even with low patient recruit-
ment, it is likely that introducing ISAC IVD to traditional diagnostic algorithm can be 
considered cost-effective, with an average cost per avoided unnecessary diet for 480 
EURs per child. To confirm the findings a larger study will be executed.
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objeCtives: Respiratory syncytial virus (RSV) is the leading cause of acute lower 
respiratory illness in children under two years of age. In Brazil, the VSR is the cause 
of 54.1% of all hospitalizations for pneumonia /bronchiolitis in infants under one 
year old, reaching up to 70% during the epidemic periods. Congenital heart disease 
(CHD) is an important risk factor for morbidity and mortality of RSV infection. This 
study performed a cost effectiveness analysis of Palivizumab (PVZ) to prevent RSV 
infection in infants undergoing cardiac surgery for correction of CHD. Methods: 
Three Systematic Reviews (SR) of literature were performed, in Medline, Cochrane 
and LILACS, for efficacy, safety of PVZ and the prevalence of RSV in infants in Brazil. 
The economic evaluation developed a decision analytic model to estimate the cost-
effectiveness ratio of using PVZ for prophylaxis of RSV infection in children under-
going cardiac surgery, from the perspective of Public Health System, with the time 
horizon of the postoperatively period. Results: Efficacy search (478 titles) showed 
that PVZ reduces hospitalization for children with CHD by 45%. Safety search (67 
titles) showed that the PVZ is safe for this population and the prevalence of RSV in 
Brazil search (120 titles) showed that in children hospitalized with lower respiratory 
tract infection there is a prevalence of 24.35% of RSV infection. The analytical model 
showed an incremental cost-effectiveness ratio of USD863.3 per day of hospitalization 
avoided and incremental cost-effectiveness ratio of USD132,398.9 per complication 
avoided. ConClusions: The prevalence of RSV in Brazil is 24.35%. PVZ was effective 
and safe to prevent severe RSV infection in children under two years of age with CHD, 
but at a high cost to avoid an outcome. Its use has shown a significant decrease in 
hospitalization of children receiving medication. Studies published worldwide are 
controversial, requiring discussion for the implementation of the therapy in Brazil.
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objeCtives: Drugs for smoking cessation are considered of great importance to the 
decline of this epidemic, as smoking is the largest preventable cause of death world-
wide. This study aimed to evaluate the cost effectiveness of varenicline compared 
with bupropion and NRT (gum and patches) in the treatment of smoking population 
from São Paulo, Brazil’s city. Methods: Effectiveness data of 6-months of treatment 
were evaluated from a sample of patients (504) in the outpatient smoking care of 
Instituto do Coraçãoem São Paulo-Brasil (InCor). Direct drug costs were extracted from 
the Health System Prices Database. A Decision Tree Model was used for the analysis of 
Cost Effectiveness (CE) and Incremental Cost-Effectiveness Ratio (ICER), considering 
varenicline monotherapy as standard. Results: The CEs obtained were BRL 1.31, BRL 
1.34, BRL 1.88, BRL 3.09 and BRL 1.98 billion in the use of varenicline monotherapy, 
varenicline associated with bupropion, bupropion associated with gum, bupropion 
associated with NRT (gum and patches) and NRT in gum and patches,respectively. 
The ICERs were BRL 1.66 billion, BRL 153 million and per patient of BRL 1,400 and BRL 
138,41 for varenicline associated with bupropion and bupropion associated with gum 
respectively and ICERs for bupropion associated with NRT and isolated NRT respec-
tively were BRL 1.65 billion and BRL 164 billion (dominant). ConClusions: According 
to the results, treatment with varenicline (monotherapy) is cost effective for all com-
parators and cost saving when compared to NRT and bupropion associated with NRT.
PRS44
CoSt-EffECtivEnESS AnAlySiS of A nEW EPinEPhRinE Auto-injECtoR foR 
thE tREAtmEnt of food-AllERgy REACtionS: dECiSion modElling uSing 
SoCiEtAl PERSPECtivE
Patel A.M, Saxena K., Holdford D.A.
Virginia Commonwealth University, Richmond, VA, USA
objeCtives: Food allergy affects around 15 million Americans with an annual eco-
nomic burden of over $25 billion. Guidelines emphasize prompt use of epinephrine 
auto-injector (EAI) for emergency treatment of allergic reactions. This study was 
executed to assess the cost-effectiveness of a new EAI device among patients expe-
riencing life-threatening food-allergy reactions. Methods: An episodic Decision-
analysis model was developed to estimate the incremental cost-effectiveness ratio 
(ICER) associated with the new EAI compared to standard EAI, from a societal per-
spective. Both EAIs contain the same active drug of equal strength, but have different 
delivery systems. The model assumed a cohort of “at-risk” patients in the US popula-
tion, with moderate-to-severe food-allergy reaction. Treatment success was defined 
as epinephrine self-injection without any errors. Data were obtained from published 
sources including patient survey studies. Direct costs (drug cost, hospitalization and 
emergency department cost) and indirect costs (lost work-productivity cost) asso-
ciated with the treatments were calculated in 2013 US$. Sensitivity analyses were 
performed on drug costs and treatment success rates. TreeAge Pro 2011 software 
represent a cost-effective alternative to salmeterol and ipratropium if daily cost for 
tiotropium can be reduced to a reasonable level in Taiwan’s National Health Insurance.
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objeCtives: Cow’s milk allergy (CMA) is the main cause of food allergy in infants, 
resulting in life-threatening events such as anaphylaxis, impairment in growth 
and quality of life. CMA symptoms are also related to other diseases, making the 
differential diagnosis crucial for an earlier effective treatment, avoiding waste of 
resources. Amino acid formula (AAF) is an alternative in treatment of CMA patients, 
but it can also be used as a diagnostic tool for children with CMA suspicion, shorten-
ing the time for diagnosis, which may reduce resources use. Our goal is to estimate 
the cost-effectiveness of an alternative practice (AP) using AAF as a diagnostic tool 
for CMA followed by treatment according to current practice, compared to those 
currently (CP) used in Brazil, under the perspective of the public health care sys-
tem. Methods: A decision model was constructed depicting the CMA manage-
ment, with a time horizon until patients turned three years old, when most of CMAs 
are resolved. Model inputs were based on literature review and opinions of allergists/
gastroenterologists/pediatricians. Exchange rate was 1.00USD = 2.30BRL. Only direct 
costs were considered, such as formula, tests, allergy treatment, medical visits and 
hospital admissions. Results were shown as incremental costs/relapses avoided. 
Deterministic and probabilistic sensitivity analyses were performed. Results: 
The CP presented rates of 25.4% and 9.3% of diseases other than CMA after 8 and 
12 weeks respectively versus 34% in 2 weeks for AP. With this difference an effec-
tive treatment could be established in a shorter time, diminishing the waste of 
resources. The final analysis showed that the AP using AAF for diagnosis is domi-
nant (USD1,345 and 900.6 non-symptomatic days) compared to CP (USD1,476 and 
876.0 non-symptomatic days). ConClusions: AP enabled an earlier CMA diagno-
sis, avoiding waste of resources, allowing the establishment of prompt effective 
treatments and leading to higher compliance with clinicians’ recommendations.
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objeCtives: Despite evidence supporting the need for oral corticosteroid use in 
the management of acute pediatric asthma exacerbations, delays in administration 
are still common. This often leads to an increase in inpatient admissions and more 
time spent in the emergency department (ED). Using data from a time-series con-
trolled trial, the objective of this study was to assess the cost-effectiveness of triage 
nurse-administered oral corticosteroids (NAC) in children presenting to the ED with 
moderate to severe asthma exacerbations prior to physician assessment. Methods: 
Resource use and cost data for 644 acutely asthmatic patients enrolled in the con-
trolled trial comparing NAC with standard care was used. Analysis assessed the per 
patient health care system costs for both the NAC (after) phase and the physician-
ordered (before) phase over the trial’s 8-month follow-up. Uncertainty around esti-
mates was assessed through nonparametric bootstrapping which allowed calculation 
of the probability that NAC was cost-effective for different threshold values. Net 
benefit regression was used to estimate the incremental net benefit (INB) adjusted 
for potential confounders for reduced time in ED. Results: NAC was dominant 
over standard care as it was both less costly (Canadian $499.24 versus $724.90) and 
mean time to clinical improvement was shorter (218 minutes versus 264 minutes). 
The probability that NAC was cost-effective was greater than 0.98 for all threshold 
values of reduction in time with symptoms. Sensitivity analyses adopting various 
alternative assumptions found only modest differences in cost savings between the 
phases, but did not change the conclusions of the analysis. Results of the net benefit 
regression provided further evidence that NAC was cost-effective. ConClusions: 
Triage nurse initiation of oral corticosteroids before physician assessment is a cost-
effective strategy for treating children with moderate to severe asthma exacerbations 
in pediatric ED.
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objeCtives: Aim of study, in accordance to Finnish Allergy Program 2008-2018, is 
to decrease food avoidance diets by 50 %. Here focus is in algorithm with IVD and 
patient history in primary care school children. Health economic benefit of CRD, ISAC, 
is evaluated. Methods: Database analysis at Härkätie Primary Care Unit, including 
2317 school children in Finland indicated that 199 children (8.6%) are on avoidance 
diet ex. celiac disease. There is 37 (1.6 %) milk and 32 (1,4%) egg free diets. Peanut and 
hazelnut allergy is indexed for 39 children and 6 are indicated as soya allergic. History 
of anaphylaxis was noted in 7. Avoidance recommendation is provided by parents 
and has direct impact in costs and patient’s quality of life. The 199 children were 
contacted by letter, and 36 (18 %) were interviewed by physician. Of those, 24 children 
agreed to take part in the study with IVD (67%). Results: An unnecessary diet was 
concluded for 15, which is 63% of children included in the study: cow’s milk 7 (29%), 
